# Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

> **NCT00044876** · PHASE2 · COMPLETED · sponsor: **Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)** · enrollment: 56 (actual)

## Conditions studied

- Leiomyoma

## Interventions

- **DRUG:** CDB-2914

## Key facts

- **NCT ID:** NCT00044876
- **Lead sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09-02
- **Primary completion:** 2007-06-16
- **Final completion:** 2015-10-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044876, "Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00044876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*